Literature DB >> 35357619

Design, synthesis, and molecular modeling of heterodimer and inhibitors of α-amylase as hypoglycemic agents.

Ved Prakash Singh1, Manisha Nidhar2, Pratima Yadav2, Ranjeet Kumar3, Priyanka Sonker2, Ashish Kumar Tewari4.   

Abstract

A series of rosiglitazone-based heterodimers were designed and synthesized, and their α-amylase and antioxidant activity was evaluated. The binding mode of the compounds at the active site of PPARγ and α-amylase enzyme was explored using MolDock docking method. In molecular docking studies against crystal structure of PPARγ (PDB code: 1FM6), compounds 10 and 13 showed interaction with amino acids Arg379, Asp379, Asn385, Ala387, Glu388, Val389, Glu390, and Lys438. Docking results of α-amylase enzyme (PDB code: 5EOF) with compounds 10 and 13 showed excellent interaction with amino acids Ala169, Lys172, Asp173, Tyr174, Val175, Arg176, and Lys178. Depending on the docking score, the designed compounds were selectively prioritized for synthesis. All synthesized compounds were subjected to in vitro α-amylase activity and antioxidant activity. Compounds 10 and 13 were to possess higher potency than acarbose, and most of the compounds showed antioxidant activity. Additionally, the most active compound 10 was evaluated for in vivo anti-diabetic activity.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Antioxidant activity; Heterodimer; Molecular modeling; PPARγ; α-amylase

Year:  2022        PMID: 35357619     DOI: 10.1007/s11030-022-10414-8

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  13 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids.

Authors:  Aslı Türe; Mustafa Ergül; Merve Ergül; Ahmet Altun; İlkay Küçükgüzel
Journal:  Mol Divers       Date:  2020-04-23       Impact factor: 2.943

Review 3.  Troglitazone and liver injury: in search of answers.

Authors:  Mario Chojkier
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

Review 4.  Anti-diabetic drugs recent approaches and advancements.

Authors:  Jayanta Dowarah; Ved Prakash Singh
Journal:  Bioorg Med Chem       Date:  2020-01-08       Impact factor: 3.641

Review 5.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

Review 6.  New hypoglycaemic agents.

Authors:  B Hulin
Journal:  Prog Med Chem       Date:  1994

Review 7.  Multiple drug targets in the management of type 2 diabetes.

Authors:  M H Moneva; S Dagogo-Jack
Journal:  Curr Drug Targets       Date:  2002-06       Impact factor: 3.465

Review 8.  Current anti-diabetic agents and their molecular targets: A review.

Authors:  Nagaraju Kerru; Ashona Singh-Pillay; Paul Awolade; Parvesh Singh
Journal:  Eur J Med Chem       Date:  2018-05-03       Impact factor: 6.514

9.  Synthesis, molecular docking and QSAR study of thiazole clubbed pyrazole hybrid as α-amylase inhibitor.

Authors:  Meenakshi Duhan; Rahul Singh; Meena Devi; Jayant Sindhu; Rimpy Bhatia; Ashwani Kumar; Parvin Kumar
Journal:  J Biomol Struct Dyn       Date:  2019-12-27

Review 10.  Diabetes mellitus: pathogenesis and treatment strategies.

Authors:  Jay S Skyler
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

View more
  1 in total

1.  Syntheses, in vitro, and in silico studies of rhodanine-based schiff bases as potential α-amylase inhibitors and radicals (DPPH and ABTS) scavengers.

Authors:  Samuel Attah Egu; Irfan Ali; Khalid Mohammed Khan; Sridevi Chigurupati; Urooj Qureshi; Uzma Salar; Muhammad Taha; Shatha Ghazi Felemban; Vijayan Venugopal; Zaheer Ul-Haq
Journal:  Mol Divers       Date:  2022-05-23       Impact factor: 2.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.